• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:刘孟娟,周陈西,王增,朱利明.83例西妥昔单抗联合放化疗不良反应分析[J].中国现代应用药学,2011,28(5):485-488.
LIU Mengjuan,ZHOU Chenxi,WANG Zeng,ZHU Liming.Analysis of Adverse Effect Induced by Cetuximab Combined with Radio-Chemotherapy in 83 Cancer Patients[J].Chin J Mod Appl Pharm(中国现代应用药学),2011,28(5):485-488.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2876次   下载 3240 本文二维码信息
码上扫一扫!
分享到: 微信 更多
83例西妥昔单抗联合放化疗不良反应分析
刘孟娟1, 周陈西1, 王增1, 朱利明2
1.浙江省肿瘤医院药剂科,杭州 310022;2.浙江省肿瘤医院化疗科,杭州 310022
摘要:
目的 分析西妥昔单抗不良反应 (ADR)发生的规律及特点。方法 利用浙江省肿瘤医院病区药房系统统计2007年1月—2010年6月期间西妥昔单抗的患者用药情况,登录电子病历系统对83例肿瘤患者使用该药后所出现的ADR进行回顾性调查,并对其发生率、出现时间、临床表现等进行统计和分析。结果 西妥昔单抗ADR发生率为61.4%,发生的平均时间19 d,ADR出现的平均累积剂量970 mg·m-2,最常见的ADR为痤疮样皮疹,发生率为59.0%。结论 西妥昔单抗治疗前后应给予有效的干预,尽量减少药物的ADR,为临床治疗的顺利进行提供保证。
关键词:  靶向治疗  西妥昔单抗  药品不良反应
DOI:
分类号:
基金项目:
Analysis of Adverse Effect Induced by Cetuximab Combined with Radio-Chemotherapy in 83 Cancer Patients
LIU Mengjuan,ZHOU Chenxi,WANG Zeng,ZHU Liming
Abstract:
OBJECTIVE To investigate the characteristics and regularity of adverse drug reaction(ADR) induced by cetuximab. METHODS Medication information of patients treated by cetuximab from January 2007 to June 2010 were retrospectively investigated by inpatient pharmacy dispensing system, then ADRs induced by cetuximab as well as relative ADR incidence rate, emergence time, clinical manifestation in 83 patients were analyzed. RESULTS The ADR incidence rate of cetuximab was 61.4%. The average of ADR emergence time was 19 days, the average accumulated dose when ADR occurred was 970 mg·m-2, the most common ADR was acneiform eruptions whose incidence rate was 59.0%. CONCLUSION Effective intervention treatment should be given before and after cetuximab therapy, so as to make the ADR incidence rate minimum and offer potent guarantee for clinical treatment.
Key words:  targeted therapy  cetuximab  adverse drug reaction
扫一扫关注本刊微信